https://twitter.com/Lakshayy_99/status/1642771523726610432?s=20
Promoter – Biocon is reducing its stake in Syngene as part of its strategic plan to unlock value and raise funds for its future growth plans. The company has been divesting its stake in Syngene in a phased manner since its initial public offering (IPO)
Syngene price is consolidating for the past 2-2.5 years ( waiting for operating leverage to kick in ) it is waiting for approval for its Active Pharmaceutical Ingredients (API) facility in Mangalore, India, which is expected in 2023.
Can go through the twitter thread , as I did not want to add repetitive data on this valuepickr thread so just added some highlights here , also if there is any other angle to it please let me know 
Disc : Tracking , planning to build position .
| Subscribe To Our Free Newsletter |
